{{noteTA|G1=ME}}

{{medical}}
{{Infobox disease
 | Name           = 弥漫大B细胞淋巴瘤
 | Image          = 
 | Caption        = 
 | DiseasesDB     = 
 | ICD10          = 
 | ICD9           = 
 | ICDO           = M9680/3
 | OMIM           = 
 | MedlinePlus    = 
 | eMedicineSubj  = 
 | eMedicineTopic = 
 | MeshID         = D016403
}}
'''弥漫大B细胞淋巴瘤'''（'''Diffuse large B-cell lymphoma''' DLBL or DLBCL）是一种常见的恶性[[淋巴瘤|淋巴瘤]]。占成人淋巴瘤患者近40%。<ref>{{Cite web |url=http://www.utdol.com/utd/content/topic.do?topicKey=lymphoma%2F20525 |title=Pathobiology of the aggressive and highly aggressive non-Hodgkin's lymphomas |access-date=2022-06-25 |archive-date=2008-01-21 |archive-url=https://web.archive.org/web/20080121104957/http://www.utdol.com/utd/content/topic.do?topicKey=lymphoma%2F20525 }}</ref>

==分型==
根据其基因活性，DLBL可分为2种<ref name="Turgeon">{{cite book
|author=Turgeon, Mary Louise
|title=Clinical hematology: theory and procedures
|url=https://archive.org/details/clinicalhematolo0004turg
|publisher=Lippincott Williams & Wilkins
|location=Hagerstown, MD
|year=2005
|pages=[https://archive.org/details/clinicalhematolo0004turg/page/285 285]–286
|isbn=0-7817-5007-5
}}</ref>或3种<ref name="pmid18765795">{{cite journal |author=Lenz G, Wright GW, Emre NC, ''et al.'' |title=Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=105 |issue=36 |pages=13520–5 |pmid=18765795 |doi=10.1073/pnas.0804295105 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=18765795|date=September 2008}}</ref>主要亚型:

* ''活化B细胞淋巴瘤''（ABC-DLBCL）
* ''生发中心B细胞淋巴瘤''（GCB-DLBCL）
* ''原发纵隔大B细胞淋巴瘤''（PMBL）

==治疗==
标准[[化疗|化疗]]方案为[[CHOP|CHOP]]方案。改良的[[CHOP-R|CHOP-R]]方案可以改善生存率<ref name="pmid17105812">{{cite journal |author=Sehn LH, Berry B, Chhanabhai M, ''et al.'' |title=The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP |journal=Blood |volume=109 |issue=5 |pages=1857–61 |pmid=17105812 |doi=10.1182/blood-2006-08-038257 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17105812 |date=March 2007 }}{{Dead link|date=2019年12月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>，尤其是对于老年人。<ref name="Turgeon"/>

==预后==
生发中心亚型的预后最好，5年生存率达60%。<ref name="Turgeon"/>

== 参考文献 ==
{{Reflist|2}}

{{-}}
{{恶性淋巴瘤}}

[[Category:淋巴瘤|Category:淋巴瘤]]